Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Tarčno zdravljenje razsejanih gastrointestinalnih stromalnih tumorjev v Sloveniji
Authors:ID Repar, Ajša (Author)
ID Matos, Erika (Author)
ID Zakotnik, Branko (Author)
Files:.pdf PDF - Presentation file, download (371,19 KB)
MD5: 43FC795013F5672AEF28F18061B05AD8
PID: 20.500.12556/dirros/eb6690c9-1beb-4da8-9454-ab6e822976ae
 
Language:Slovenian
Typology:1.03 - Other scientific articles
Organization:Logo OI - Institute of Oncology
Abstract:Gastrointestinalni tumorji (GIST) so redke neoplazme mezenhimskega izvora, ki na celični površini izražajo transmembranski receptor KIT, produkt c-kit protoonkogena. Pri patogenezi GIST so pomembne mutacije KIT. Njihova posledica je aktivacija KIT signalne poti, ki vodi do nekontrolirane proliferacije celic in rezistenco na apoptozo. Do nedavnega je bilo radikalno kirurško zdravljenje edina uspešna oblika zdravljenja za manjše in dobro omejene GIST, za razsejano bolezen pa ni bilo uspešne terapije. Z odkritjem imatinib mesilata in kasneje sunitiniba, ki inhibirata KIT signalno pot, se je prognoza bolnikov z GIST močno izboljšala. Srednje preživetje bolnikov z razsejano boleznijo se je iz pol leta povečalo skoraj na pet let. Od leta 2001 smo na Onkološkem inštitutu Ljubljana uspešno zdravili 51 bolnikov. Srednje preživetje naših bolnikov je 66 mesecev. To lahko pripisujemo timski obravnavi bolnikov, ki je glede na velikost Slovenije in nizko incidenco GIST smiselna na enem mestu.
Publication status:Published
Publication version:Version of Record
Year of publishing:2008
Number of pages:str. 13-16
Numbering:Letn. 12, št. 1
PID:20.500.12556/DiRROS-9009 New window
UDC:616-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-6X9KDVNK
COBISS.SI-ID:618107 New window
Copyright:by Authors
Publication date in DiRROS:31.08.2018
Views:3455
Downloads:846
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Targeted Treatment of Metastatic Gastrointestinal Stromal Tumors in Slovenia
Abstract:Gastrointestinal stromal tumors (GIST) are rare mesenchymal neoplasms. They express the cell-surface transmembrane receptor KIT, a product of the c-kit proto-oncogene. Frequent mutations of KIT result in the constitutive activation of KIT signaling, which leads to uncontrolled cell proliferation and resistance to apoptosis. Until recently, surgery was the only successful treatment for localized GIST, while there was no effective treatment for metastatic disease. With the discovery of imatinib mesylate and sunitinib, selective inhibitors of certain protein tyrosine kinases, the prognosis of unresectable or metastatic GIST has substantially improved from a median survival of 6 months to almost 5 years. From 2001, we have successfully treated 51 patients with GIST at the Institute of Oncology Ljubljana. Median survival of our patients is 66 months. This treatment success can be attributed to the fact that all Slovenian metastatic GIST patients were treated by the multidisciplinary sarcoma team at our institution, which is, for a small country as Slovenia, a rational approach to the management of a rare disease.


Archive

niGradiv

Back